As the healthcare, veterinary, and biotechnology sectors are searching for effective alternatives to antibiotics in the fight against antimicrobial resistance (AMR), the global Phage Therapy Market is gaining rapid momentum. According to a recent market analysis by Technavio, the phage therapy market is expected to grow at a compound annual growth rate (CAGR) of 17.41% between 2023 and 2028, with a total market expansion of USD 51 million during the forecast period.
Escherichia coli to Dominate the Product Segment
Among product categories, phage therapies targeting Escherichia coli are projected to lead the market between 2024 and 2028. The dominance of this segment reflects the global clinical and industrial burden of E. coli, which is a major cause of urinary tract infections, gastrointestinal diseases, foodborne outbreaks, and livestock infections.
Other important bacterial targets contributing to market growth include:
- Staphylococcus aureus
- Salmonella
- Pseudomonas aeruginosa
- Klebsiella pneumoniae
- Streptococcus species
- Clostridium difficile
Key Factors Driving Market Growth
The phage therapy market is being propelled by several critical drivers:
- Advantages of phage therapy over antibiotics, including high specificity, reduced disruption of the microbiome, and effectiveness against drug-resistant bacteria
- Rising applications in animal health, particularly in livestock, poultry, aquaculture, and veterinary medicine
- Expanding use in human health, especially for chronic, recurrent, and multidrug-resistant infections
- Growing interest in phage-based diagnostics and food safety applications
Significant investment activity further underscores confidence in the sector. In a recent development, the AMR Action Fund and Deerfield Management committed an investment of around USD 30 million in Adaptive Phage’s Series B1 funding round. This investment supports the clinical advancement of phage therapeutics aimed at treating AMR infections—one of the most urgent global public health challenges.
Market Segmentation Overview
By Geography
- Europe (including the UK, France, Netherlands)
- North America (US, Canada)
- Asia (China, India, Japan, South Korea)
- Rest of the World (ROW)
By Disease Indication
- Urinary tract infections
- Wound and skin infections
- Gastrointestinal infections
- Respiratory infections
- Other bacterial diseases
By Application
- Human health
- Animal health
- Food industry
- Agriculture
- Aquaculture
- Diagnostics
Challenges Facing the Phage Therapy Market
Despite strong growth prospects, the market faces several limitations:
- High quality and safety requirements for phage preparations
- The potential evolution of bacterial resistance to phages
- Strict regulatory oversight and the absence of standardized global approval pathways
Addressing these challenges will be critical to ensure scalable commercialization and broader clinical adoption.
Market Outlook
Today, the phage therapy market is an increasingly important segment of the global pharmaceuticals and biotechnology industry, driven by advances in phage engineering, genomics, bioinformatics, and synthetic biology. As antibiotic resistance continues to rise and regulatory frameworks evolve, phage therapy is poised to play a crucial role in next-generation antibacterial strategies across both human and animal health.
Find the complete review article here
